关于冠状动脉微血管功能障碍治疗策略的最新评论
Chinmay Khandkar1, Rajan Rehan1, Jayant Ravindran2
1Concord Hospital, Concord 2139, NSW, Australia; University of Sydney, Camperdown 2050, NSW, Australia; Royal Prince Alfred Hospital, Camperdown 2050, NSW, Australia.
International journal of cardiology
|March 11, 2025
概括
冠状动脉微血管功能障碍 (CMD) 的治疗有效性有限. 虽然奎那普利和拉诺拉改善了冠状动脉流量储备和胸痛,但分析缺乏统计学意义,表明需要更高质量的试验.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
- 临床试验 临床试验
背景情况:
- 冠状动脉微血管功能障碍 (CMD) 是心痛的一个重要原因,治疗选择有限.
- 准确的评估和严格的CMD定义对于评估治疗至关重要.
研究的目的:
- 系统地审查和评估冠状动脉微血管功能障碍 (CMD) 的当前治疗方法.
- 根据最近的共识指南和准确的微血管评估方法,提供对治疗方法的当代评估.
主要方法:
- 一个系统的审查和对成年患者的前性试验的元分析记录的CMD.
- 使用冠状动脉流量储备 (CFR) /心肌输液储备 (MPR) <2.5和/或微血管阻力指数 (IMR) >25来定义CMD.
- 通过使用Cochrane风险偏差工具来评估研究质量;主要终点是CFR/MPR/IMR得分的变化和西雅图心痛问卷 (SAQ).
主要成果:
- 包括14项试验,涵盖9种治疗方法.
- 奎那普里尔和拉诺拉显著改善了CFR和胸痛.
- 罗纳拉试验的元分析显示,微弱的,非统计学上显著的积极效应 (p=0.20).
结论:
- 对CMD治疗的总体证据质量很低.
- 显著缺乏可靠的数据,强调需要高质量的临床试验.
- 目前对CMD的治疗选择仍然有限.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...


